Ascletis Announces Dosing of the First Patient in Phase III

HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. today announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to...

Related Keywords

China , Huashan , Henan , Shaoxing , Zhejiang , Hangzhou , Hong Kong , Jinzij Wu , , Fudan University , Ascletis Pharma Inc , Prnewswire Ascletis Pharma Inc , Sagimet Biosciences Inc , Hong Kong Stock Exchange , Huashan Hospital , Global Assessment , Greater China , Sagimet Biosciences , Markets ,